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Cognitive rehabilitation in multiple sclerosis (MS) has been reported to induce
neuropsychological improvements, but the persistence of these effects has been
scarcely investigated over long follow ups. Here, the results of a multicenter randomized
clinical trial are reported, in which the efficacy of 15 week domain specific cognitive
training was evaluated at 2 years follow up in 41 patients. Included patients were
randomly assigned either to domain specific cognitive rehabilitation, or to aspecific
psychological intervention. Patients who still resulted to be cognitively impaired at 1 year
follow up were resubmitted to the same treatment, whereas the recovered ones were
not. Neuropsychological tests and functional scales were administered at 2 years follow
up to all the patients. Results revealed that both at 1 and at 2 years follow up more
patients in the aspecific group (18/19, 94% and 13/17, 76% respectively) than in the
specific group (11/22, 50% and 5/15, 33% respectively) resulted to be cognitively
impaired. Furthermore patients belonging to the specific group showed significantly less
impaired tests compared with the aspecific group ones (p = 0.02) and a significant
amelioration in the majority of the tests. On the contrary patients in the aspecific group
did not change. The specific group subjects also perceived a subjective improvement
in their cognitive performance, while the aspecific group patients did not. These results
showed that short time domain specific cognitive rehabilitation is a useful treatment for
patients with MS, shows very long lasting effects, compared to aspecific psychological
interventions. Also subjective cognitive amelioration was found in patients submitted to
domain specific treatment after 2 years.
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INTRODUCTION
Patients affected with multiple sclerosis (MS) often have
a certain degree of cognitive impairment. Approximately
40–70% of patients present a certain degree of cognitive
deficit, independently from disease duration, disease severity
and physical disability (Chiaravalloti and DeLuca, 2008). This
frequently contributes to the loss of employment, reduced social
and working abilities and worsened quality of life (Pompeii
et al., 2005; Putzki et al., 2009). The main affected cognitive
areas are attention, information processing speed, memory and
executive functions (Calabrese, 2006; Chiaravalloti and DeLuca,
2008; Duque et al., 2008; Prakash et al., 2008). The spontaneous
evolution of cognitive deficits in MS is known to be worsening,
as shown by a 10 years longitudinal study conducted on patients
who were in large measure untreated, reporting the increase
in the number of moderately or severely impaired MS patients
and a reduction of mildly impaired ones over time. Among
clinical predictors, incipient cognitive decline seems to be the
major risk factor for further patents’ deterioration in the short-
term. In the long-term, the likelihood increases that also patients
with initial cognitive preservation may deteriorate (Amato et al.,
2006b).
Although cognitive deficits are prominent and detrimental
in MS, surprisingly few studies investigated the effectiveness of
cognitive training (Jønsson et al., 1993; Plohmann et al., 1998;
Fink et al., 2010; Mattioli et al., 2010a; Amato et al., 2014;
Chiaravalloti and DeLuca, 2015). Despite differences emerged
between the results of early published studies—mainly depending
on methodological issues, such as clinical heterogeneity across
patients in terms of disability, type of cognitive impairment, type
ofMS and type of immunomodulatory drug they were prescribed
(Thomas et al., 2006)—the most recent investigations provided
convergent support to the usefulness of cognitive rehabilitation
in MS (Rosti-Otajärvi and Hämäläinen, 2014). Particularly,
episodic memory (Chiaravalloti et al., 2013), autobiographical
memory (Ernst et al., 2015) and attention abilities (Mattioli
et al., 2010a, 2012; Amato et al., 2014) and executive functions
(Mattioli et al., 2010a) have been shown to significantly
improve after a domain specific cognitive training in randomized
clinical trials—either compared to no treatment or to a control
treatment. The positive effects of these cognitive trainings have
been reported both immediately after the end of the treatment
(Mattioli et al., 2010b; Hubacher et al., 2015) and 6 months
after the end (Mattioli et al., 2012; Chiaravalloti et al., 2013;
Rosti-Otajärvi et al., 2013). An independent improvement also
in depression—a frequently associated disorder in MS—and
quality of life have also been shown after cognitive interventions
(Mattioli et al., 2010a, 2012).
However, the above mentioned studies were all performed
by one single center and only in one recent study (Mattioli
et al., 2015) a multicenter approach has been used, providing
supporting evidences of the reliability of the domain specific
approach (Sprague et al., 2009). This study, the Sclerosi
Multipla Intensive Cognitive Training (SMICT) is a multicenter
randomized Italian clinical trial on relapsing remitting (RR)
patients. It was aimed at comparing the efficacy of a domain
specific cognitive training with a non specific psychological
treatment over 2 years follow up. Preliminary data of this
collaborative study with the results of the 1st year follow up,
showed that patients treated with the domain specific approach
had a significantly lower number of impaired cognitive tests
and resulted to be cognitively recovered in a significantly
higher proportion compared to those ones submitted to the
non-specific psychological intervention (Mattioli et al., 2015).
Furthermore, all the patients of the study were prescribed the
same immunomodulatory drug, (in fact, different therapeutic
regimens in previous trials could have been a confounding
variable). Through the persistence at 1 year of the positive effects
of domain specific cognitive interventions has been published,
the exact need for treatment beyond the 1st year of follow up
still needs to be further investigated and the possible beneficial
effect of repeated boosters of cognitive training in MS patients
still needs to be investigated as well.
The aim of the current article is to provide final results of
the SMICT study over 2 years follow up in MS, evaluating the
persistence over 2 years of cognitive improvement induced by the
domain specific cognitive training. Also the possible efficacy of a
repeated cognitive treatment in the 2nd year of follow up will be
examined.
MATERIALS AND METHODS
Subjects
The Randomized Clinical Trial (Spedali Civili of Brescia trial
Register NP: 560) was performed according to the Helsinki
Declaration and after the approval of the Ethical Committee
(Comitato Etico Provinciale di Brescia, January 2010). Patients’
enrolment started on June 2010 and ended 31 December 2011.
It involved 10 MS centers in Italy. Patients affected with MS,
according to Poser and Brinar (2001) criteria with a RR course
were included in the study, after their signed informed consent
was obtained. To participate in the study, all patients needed to
have been prescribed interferon beta 1A 44 mcg 3 times/week
no later than 6 months before, in order to have the same
drug regimen in patients. This first line therapeutic regimen
was chosen, as it has been shown to be effective on several
neuropsychological measures (Amato et al., 2013). Patients were
included only if impaired (age corrected z score < −1.5 SD to
norms) in at least one of the tests included in the Italian version
of the Rao Brief Repeatable Battery and Stroop test. Exclusion
criteria were dementia (excluded by means of anamnestic
reports as well as MMSE >24 in patients), previous or present
psychiatric disorders (requiring pharmacological treatment) and
clinically evident relapse in the previous 6 months. For the
included patients, the disease duration, the disability in the
Expanded Disability Status Scale (EDSS; Kurtzke, 1983), the
relapse rate and steroid consumption (grams of intra venous
methylprednisolone) in the previous year were registered.
Neuropsychological Evaluations
Three neuropsychological evaluations were performed for each
patient: T0 at baseline before enrolment, T12 after 1 year and T24
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after 2 years from the baseline. The Italian version of the Rao’s
Brief Repeatable Battery (Amato et al., 2006a), including Paced
Auditory Serial Addition Task (PASAT 2′′, PASAT 3′′), Simbol
Digit Modality Test (SDMT), Spatial Recall Test (SPART) 10/36
and Delayed Recall (SPART D), Selective Reminding Test Long
Term storage (SRT LTS), Consistent Long Term Retrieval (SRT
CLTR), Delayed Recall (SRT DR), the Controlled Oral Words
Association (COWA) with the Phoneme (P) and Category (C)
modalities (Mattioli et al., 2010a) and Stroop test (Barbarotto
et al., 1998). Alternative forms, when available, were used, in
order to avoid test retest effects and learning effects (Goretti
et al., 2014). All the tests were corrected by age and education,
according to published norms. A test was considered impaired, if
its corrected score fell below−1.5 SD.
In addition, three functional scales were administered,
in order to evaluate the fatigue (Modified Fatigue Impact
Scale, mFIS; Kos et al., 2006), the possible deflection of
mood (Montgomery-Asberg Depression Rating Scale, MADRS;
Montgomery and Asberg, 1979) and the quality of life (Multiple
Sclerosis Quality of Life Questionnaire, MSQoL; Solari et al.,
1999) at the same intervals.
In order to measure the patients’ subjective perception of
cognitive amelioration after treatment, the item 6 of MADRS has
been selected and used: it requires the patient to rate on a 6 point
Likert scale his/her difficulties in collecting one’s thoughts, where
0 means ‘‘no difficulty in concentrating’’ and 6 means ‘‘unable to
read or converse without great difficulty’’ and compared between
T0 and T24.
Treatments
Patients were randomly assigned to Specific Treatment Group
(SG) or to Aspecific Treatment Group (AG), for 15 consecutive
weeks with 2 weekly 60’ sessions. Randomization (according to
a computer-generated list of random number) and statistical
analysis of data were carried out by an independent center, from
whom all the Centers received the patients’ number.
Specific Treatment
Specific treatment was administered according to the impaired
neuropsychological function: Plan a Day software of the
Rehacom1 was used if a patient resulted impaired in executive
functions (that is if his/her poor score was in the Stroop test
or in the COWA P or COWA/C); Memory software of the
same package was used if the patient was impaired in either
the SRT or SPART verbal or spatial memory measures and
the previously described 29 A/IP training, if he/she resulted
impaired in attention/speeded information processing domain
(pathological PASAT 2′′, PASAT 3′′, SDMT). If a patient was
impaired in more than one domain, all the single domain
trainings were balanced in the hourly session each time. Exercises
complexity was adapted each time to the severity of each single
patient’s impairment in the selected domain, with the aim that
the exercise had to be challenging in each treatment session.
1www.schuhfried.at
Plan a Day
The Plan a Day procedure trains the patient’s ability to
organize, plan and develop solution strategies, employing
realistic simulations of a set of scheduled dates and duties to be
organized at specific places in a virtual small city map. Times
for planning and schedules are registered for each patient at
each session and only improvement and acquisition of sufficient
planning abilities for fulfilling all the appointments required
led to an improved level in the following treatment session.
Fifty four levels of increasing complexity are available, in order
to challenge any grade of impairment. This was considered a
strategic behavior acquisition. For further description of the
treatment see Mattioli et al. (2015).
Memory
Patients were asked to give answer to multiple choice or open
questions about tales of increasing length, which were presented
on the PC, whose complexity was chosen on the basis of the
patient’s memory impairment. Ten levels of difficulty—also with
interfering condition of two or three tales alternatively presented
with the other tales’ questions—were progressively presented to
the patients.
A/IP Training
A specific speeded information training with increasing velocity
(from 4000 to 1800 ms interval), which has been shown to be
effective in patients with brain injuries, was used, consisting of a
modified PASAT task with numbers, words and months of the
year, according to Serino et al. (2006) procedure.
Aspecific Training
The A treatment (not domain specific intervention, but a generic
psychological intervention, considered as control treatment) was
conducted by the psychologist addressing the following items
with the patient: the patient’s disease perception (with the
aid of scientific articles dealing with MS), eventual limitation
in the patient’s occupation due to MS, possible difficulties
on his/her job, problems with the patient’s family life and
leisure activities, specific problems of the patient’s due to
MS (i.e., sexual, affective). The aim of this sort of psycho
education was not to specifically treat a cognitive ability,
but rather to discuss with the patient about the functional
impairment due to MS, avoiding to treat depression or to
have any behavioral or psychoanalytic approach. This type of
psycho educational treatment, considered as a control treatment
have been accepted as ethical by the Ethical Committees of
all the Centers, as no sure evidences exist till now about
the superiority of domain specific treatments of memory,
attention and executive functions on the aspecific psychological
approaches in MS.
All the treating psychologists were trained by attending 10
consecutive training meetings with the psychologists of the
coordinator center.
The same treatment administered after randomization was
repeated in the 2nd year of the study, after T12 evaluation,
only if a patient resulted to be still impaired in at least one
neurpsychological test.
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Patients’ neuropsychological evaluations and treatments
were done by different neuropsychologists and performed
in a quiet room, according with standardized published
procedures, with maximum attention paid by the
neuropsychologists in order to avoid interference from
possible low motivation of patients on performance. All
the patients were reminded about the study protocol
in each session, in order to refresh the context of the
evaluations.
Statistical Analysis
A sample size of 14 patients for each group was necessary
(Faul et al., 2007) in order to have a 5% significance
level and a 90% statistical power. Descriptive statistics
are expressed as median and/or means ± SD. Due to
the nature of the variables and the sample size, non-
parametric tests were performed. The two patients’groups
were compared using Mann-Whitney’s statistic test for
quantitative variables and Fisher’s exact test for qualitative
variables.
Pearson chi-squared test was applied to qualitative data.
Repeated measures within group were evaluated by Wilcoxon
signed-rank test (over two-time point) and by Friedman’s
test (over the three-time point). Repeated measures mixed
models were applied to each variable to take into consideration
simultaneously the effect of treatment, time and their interaction.
All statistical analyses were performed using STATA/SE version
12.1 software and a p < 0.05 was considered significant. A
Poisson multivariate regression model has been used to analyze
the relationship between number of pathological tests and
treatment, using EDSS as a covariate.
RESULTS
The AG consisted of 19 patients both at T0 and at T12. Eighteen
of them resulted to be still impaired at T12 (that is they had at
least one impaired test in the neuropsychological battery), two
of which refused to repeat the neuropsychological evaluation at
T24, so 16 patients in the AG repeated the aspecific treatment. In
the SG, which at T0 and T12 consisted of 22 subjects, of whom
11 were still impaired at T12, 8 subjects refused to repeat the
neuropsychological evaluation and only three patients repeated
the treatment (with the same domain specific intervention as
in the 1st year). Figure 1 reports the CONSORT diagram.
Comparing the number of patients who were still cognitively
impaired at T12 between groups, a significantly higher number in
the AG than in SG was found (16/17, 94% vs. 3/15, 20%, Pearson
test p = 0.014). Also at T24 a significantly higher number (13/17)
of patients in the AG than in the SG (5/15) resulted to be still
cognitively impaired (Pearson test p = 0.014). This sample was
considered for statistical analysis of single tests’ scores.
As previously reported (Mattioli et al., 2015) baseline (T0)
clinical characteristics of patients did not differ between groups
in terms of disease duration, age, education, EDSS, steroid
consumption and number of relapses. At T12 only EDSS score
was changed between groups, which resulted to be higher in
patients submitted to the Aspecific Treatment compared with
patients submitted to the Specific Treatment (Table 1). Within
group change revealed a worsened EDSS in AG at T24 (mean
EDSS 3.47, SD 1.76; repeated measures mixed models: significant
effect of both group and time, as well as interactions: p = 0.003,
p = 0.019, p = 0.002) and an unchanged EDSS in SG. However,
the number of relapses was not significantly different between
the two groups at T24 (Mann Whitney p = 0.99), with a decrease
compared with the number in the previous year in both groups.
Similarly, steroid consumption decreased in the 2nd year follow
up, not significantly different between groups (Mann Whitney
test p = 0.3), indicating an overall similarity between disease
physical severity between the groups.
As shown in Table 2 the number of impaired tests in AG was
not significantly changed between T0 and T24 (p = 0.51), while
in the SG a significant reduction of impaired tests was observed
(p < 0.001). Considering the comparison between AG and SG
also at T12 in the number of impaired tests a significant reduction
of them was found in the SG (Table 2). In addition, a between
group comparisons of the number of pathological tests at T24
further confirms less impaired tests in SG compared with the AG
(0.75 ± 1.34, 2.29 ± 2.52, p = 0.02). However, in a multivariate
analysis, taking into account EDSS as a covariate, the difference
in the number of pathological tests between AG and SG group
loses its statistical significance (p = 0.089).
On the other hand, no differences emerged in MSQoL, mFIS
and MADRS between groups at T24 (Table 3).
Also single tests’ performance at T24 revealed significantly
better performances of SG group compared to AG in SDMT
(35 vs. 46, p = 0.02) and COWAL (30 vs. 35, p = 0.006), with
a trend toward significance in SPART DR (five vs. seven, p
= 0.055). Subjects in SG significantly improved their scores in
almost all neuropsychological tests after both 1 and 2 years
(Table 4), whereas subjects in AG did not significantly improved
their scores in none of the tests. In repeated measures mixed
models, interactions between treatment and time was statistically
significant for PASAT 3′′, SPART DR, SDMT and Stroop test
and marginally significant for SPART 10/36 (p = 0.0649) and
SRT LTS (p = 0.0556). These results confirm the significant
difference on the neuropsychological tests between the two
groups at the different follow ups, showing differences at T12 and
at T24. Noteworthy, considering only the three patients of the
SG, who, as being impaired at T12, were submitted to repeated
rehabilitation the second time, they resulted to be unchanged at
T24, in terms of number of impaired tests. The patients were all
impaired in memory (of them one also impaired in attention and
another in executive function), but, due to the small number, no
statistical analysis on the effects of the training between domains
was carried on.
Although the total MADRS score did not differ between
groups, the results on MADRS item 6 measuring the subjective
perception of cognitive deficits, resulted to be significantly
reduced in SG (median T0 2, median T24 0; p = 0.0182Wilcoxon
signed rank test) and unchanged in the AG (median T0 2, median
T24 2; p = 0.88Wilcoxon signed rank test) and to be significantly
better in SG than in the AG at T24 (p= 0.291MannWhitney test),
showing a better subjective perception of cognitive performance
in SG.
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FIGURE 1 | Consort diagram of the study.
TABLE 1 | Characteristics of patients at T12.
AG (n = 17) SG (n = 15) p-value∗
Median Mean ± SD Median Mean ± SD
Age (years) 49 44.88 ± 9.96 47 44.80 ± 8.69 0.75
Years of education 13 12.12 ± 3.62 10 10.93 ± 3.17 0.41
Disease duration (months) 60 87.18 ± 74.83 30 67.20 ± 88.77 0.10
Number of relapses (previous year) 0 0.53 ± 0.94 0 0.33 ± 0.62 0.72
EDSS 3 2.97 ± 1.49 2 1.63 ± 0.95 0.0094
Steroid (gr)# 0 2.29 ± 4.40 0 0.71 ± 1.82 0.30
∗Mann-Whitney test. AG, Aspecific Treatment Group; SG, Specific Treatment Group; EDSS, Expanded Disability Status Scale. #Methylprednisolone consumption in the
1st year of the study.
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TABLE 2 | Number of pathological tests at baseline (T0) and after rehabilitation (T24), and between groups comparison (∗) at T24.
AG (n = 17) SG (n = 15)
T0 T12∧ T24 T0 T12 T24
m m m p-value∗∗ m m m p-value∗∗ p-value∗
Number of pathological tests 2 3 2 0.5169 2 0 0 0.0006 0.0162
∗∗Wilcoxon signed-rank test. ∗Mann-Whitney test at T24. ∧Wilcoxon signed rank test: AG T0 vs. T24 p = 0.51; SG T0 vs. T24 p = 0.006.
DISCUSSION
The main result of the present study is that domain specific
cognitive rehabilitation can be effective and can sustain
significant cognitive improvements up to 2 years in patients
with RR MS. Specific exercises aimed at treating the impaired
cognitive domain are shown to induce significantly better
results both on cognition and on subjective perception of
cognitive impairment in patients, compared with non domain
specific psychological interventions. Results showed the greater
amelioration both considering the reduction in the number
of impaired neuropsychological tests and the improvement in
single tests’ scores over time. Particularly, nearly all (94%)
patients assigned to aspecific treatment and only 20% of
those assigned to the specific treatment, needed the repeated
rehabilitation in the 2nd year of follow up. This indicates that
the domain specific intervention provided in the 1st year caused
beneficial effects lasting up to 2 years. Notably, the only three
patients, who—being still impaired at T12—needed a repeated
treatment, did not change in severity their cognitive impairment,
measured as the number of impaired tests. The uselessness of
repeated treatments in neuropsychological rehabilitation of MS
is in line—although with longer time of follow up—with the
conclusions of Chiaravalloti et al. (2013), who found no effects of
repeated booster sessions ofmemory rehabilitation in their study.
Moreover, after 2 years, patients assigned to the SG
showed fewer impaired neuropsychological tests compared to
those assigned to AG and also had a significantly better
performance in tests measuring information processing speed
and executive functions. Finally SG patients perceived a
subjective improvement in their cognitive performance, whereas
AG patients did not. This finding is relevant in MS, as shows
that appropriately conducted cognitive rehabilitation can be able
to reduce the worsening spontaneous evolution of cognitive
impairment of MS patients and beneficially impact on their
disease relate disability over time.
TABLE 3 | T24 MSQoL, mFIS and MADRS scores in AG and SG.
AG (n = 17) SG (n = 15)
median median p-value∗
MSQoL 140 161 0.14
mFIS 32 20 0.27
MADRS 5 5 0.34
EDSS 3 1.5 0.005
∗Mann-Whitney test at T24.
The cognitive improvement found in SG is, in our opinion,
only ascribed to the type of the treatment assigned, as the
other clinical variables were not different between groups, as
well as the type of the pharmacological treatment used and the
disease severity. Although, it is worth noting that a possibly
higher disease activity in AG compared to SG cannot be
totally ruled out: throughout the study, EDSS—relatively low
in both groups—worsened in AG and remained substantially
stable in SG. On the other hand steroid consumption and
relapse rates were not different between groups across 2 years
follo up. Furthermore, it is known that EDSS relies more on
physical than on cognitive disability; so it is possible that,
at individual level, physical disability worsened more in AG
patients due to less response to immunomodulatory drug instead
of more active disease. Furthermore, a different response to
interferon can be hypothesized in AG compared to SG and
also possible spinal or cerebellar new lesions (that would
not be relevant under a cognitive point of view) could have
also been responsible for motor/EDSS worsening). Overall,
it is reasonable to conclude that—although neuroradiological
data on new lesions are missing in this study-, disease
activity relevant for cognitive worsening can reasonably be
considered similar between groups; not the same for motor
disability.
The possibility of successfully rehabilitate MS patients’
cognitive impairment with domain specific PC assisted,
replicable and easily to administer rehabilitative programs in
the clinical setting, with long standing results up to 2 years,
has never been demonstrated till now. This prompts future
research with larger samples of patients, as the main limitation
of our study is the low number of included MS subjects. The
main reasons of this, is in our opinion, the inclusion criteria
and probably for some MS centers, the logistic problems met by
patients whose psychologist was accessible within the Hospital,
compared with those who met the psychologist outside, in
rehabilitation clinics. Centers whose neuropsychologist was
easily accessible in rehabilitative structures had in fact greater
inclusions and less drop outs. A future issue will be the possibility
of structuring home based trainings, monitoring the effective
practice by each patients, both in terms of correctness and
of number of exercises performed at home. This could give
additional interesting data on the effects of intensive cognitive
rehabilitation in MS.
Another limitation of this study is the type of the control
aspecific treatment. Although in randomized clinical trials
dealing with neuropsychological rehabilitation, a psychological
control treatment is difficult to be set and deserves intrinsic
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TABLE 4 | Comparison of neuropsychological tests median raw scores at baseline (T0), after 1 year rehabilitation (T12) and after 2-years rehabilitation
(T24).
AG (n = 17) SG (n = 15) T 24: AG vs. SG
T0 T12 T24 T0 T12 T24 p-value∗
PASAT3 37 36 38 36 45 44 0.1619
PASAT2 23 29 30 24 35 32 0.1302
SPART10/36 18 19 19 15 22 21 0.1497
SPARTDR 6 6 5 4 7 7 0.0559
SRTLTS 33 40 37 30 44 46 0.2487
SRTCLTR 24 28 26 23 34 33 0.5966
SRTDR 8 8 8 7 9 8 0.7741
SDMT 40 40 35 44 49 46 0.0256
COWAL 28 30 30 34 35 35 0.0068
COWAC 40 42 41 38 42 45 0.3155
Stroop 20 27 25 23 30 30 0.1441
∗Mann Whitney test. Between groups comparison (∗) at T24.
limitation, it is overtly recognized to be useful and recommended
as a comparator treatment (Rosti-Otajärvi and Hämäläinen,
2014). The intrinsic limitation of a non domain specific
psychological control treatment relies mainly in the fact
that patients submitted to it may well have become aware
of the psycho educational nature of this treatment, and
may have consciously or unconsciously inferred that they
were receiving the placebo treatment. This, in the specific
case of our study, may have mainly impact the subjective
perception of cognitive improvement we found in AG, more
than the objective neuropsychological evaluation at follow
ups.
In this study, similarly to others (Hämäläinen and Rosti-
Otajärvi, 2014; Chiaravalloti and DeLuca, 2015) not only
objective neuropsychological tests, but also subjective perception
of the patients’ cognitive improvement was measured. Patients
in the SG subjectively perceived higher improvement in
cognitive abilities than AG, although the scale we used was
relatively simple and in the future better functional scales
are welcome.
In conclusion, despite some limits, this is the first study
evaluating the persistence of the cognitive improvement induced
by a domain specific cognitive rehabilitation in MS with a follow
up of 2 years. Despite limitations, results interestingly show a
significant effect of this treatment in a multi center setting and
its persistence after 2 years.
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